Testing effectiveness (Phase 2)Study completedNCT01481129
What this trial is testing
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Who this might be right for
Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI) 22